Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population-based cohort study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 1, 2015, Pages 155-162

  Chang, Chia Hsuin ^a,b,c   Chang, Yi Cheng ^b,c   Lee, Yen Chieh ^a,d   Liu, Ying Chun ^a   Chuang, Lee Ming ^a,b,c   Lin, Jou Wei ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Acute hepatic injury; Atorvastatin; Chronic liver disease; National health insurance; Statin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIGOUT AGENT; ATORVASTATIN; DIGOXIN; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; ADULT; AGED; CHRONIC DISEASE; COMPLICATION; DRUG-INDUCED LIVER INJURY; FOLLOW UP; INCIDENCE; LIVER DISEASE; MALE; MIDDLE AGED; RISK; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TAIWAN; TIME;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER DISEASES; MALE; MIDDLE AGED; PYRROLES; RISK; SEVERITY OF ILLNESS INDEX; TAIWAN; TIME FACTORS;

EID: 84919658520     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12657     Document Type: Article

References (44)

1. MacDonald JS, Gerson RJ, Kornbrust DJ etal. Preclinical evaluation of lovastatin. Am. J. Cardiol. 1988; 62: 16J-27.
2. Horsmans Y, Desager JP, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol. Toxicol. 1990; 67: 336-339.
3. Armitage J. The safety of statins in clinical practice. Lancet. 2007; 370: 1781-1790.
4. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004; 24: 584-591.
5. Bradford RH, Shear CL, Chremos AN etal. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 1991; 151: 43-49.
6. LaRosa JC. Cholesterol lowering and morbidity and mortality. Curr. Opin. Lipidol. 1995; 6: 62-65.
7. Herd JA, Ballantyne CM, Farmer JA etal. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. 1997; 80: 278-286.
8. Serruys PW, de Feyter P, Macaya C etal. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 287: 3215-3222.
9. Furberg CD, Adams HP Jr, Applegate WB etal. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) research group. Circulation. 1994; 90: 1679-1687.
10. Downs JR, Clearfield M, Weis S etal. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/texas coronary atherosclerosis prevention study. JAMA. 1998; 279: 1615-1622.
11. LaRosa JC, Grundy SM, Waters DD etal. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352: 1425-1435.
12. I Cannon CP, Braunwald E, McCabe CH etal. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
13. Pedersen TR, Faergeman O, Kastelein JJ etal. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294: 2437-2445.
14. Amarenco P, Bogousslavsky J, Callahan A 3rd etal. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006; 355: 549-559.
15. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am. J. Cardiol. 2006; 97: 77C-81.
16. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. Available from URL: http://www.fda.gov/drugs/drugsafety/ucm293101.htm, 2012.
17. Pfizer Inc. Revised. Atorvastatin drug package insert.2009.
18. Merck & Co., Inc. Lovastatin drug package insert.2014.
19. Bristol-Myers Squibb Company. Pravastatin drug package insert. 2013.
20. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 2000; 133: 592-599.
21. Nseir W, Shalata A, Marmor A etal. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig. Dis. Sci. 2011; 56: 3439-3449.
22. Bader T. Yes! Statins can be given to liver patients. J. Hepatol. 2012; 56: 305-307.
23. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment. Pharmacol. Ther. 2008; 27: 274-282.
24. Agarwal VK, McHutchison JG, Hoofnagle JH. Drug-induced liver injury network. Important elements for the diagnosis of drug-induced liver injury. Clin. Gastroenterol. Hepatol. 2010; 8: 463-470.
25. Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am. J. Med. Sci. 2010; 340: 89-93.
26. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol. Drug. Saf. 2012; (Suppl. 2): 138-147.
27. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46: 1453-1463.
28. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004; 126: 1287-1292.
29. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 2006; 4: 902-907. quiz 806.
30. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am. J. Med. Sci. 2005; 329: 62-65.
31. Avins AL, Manos MM, Ackerson L etal. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug. Saf. 2008; 31: 325-334.
32. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012; 56: 374-380.
33. Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig. Liver. Dis. 2006; 38: 772-777.
34. Tolman KG. The liver and lovastatin. Am. J. Cardiol. 2002; 89: 1374-1380.
35. Teschke R, Frenzel C, Wolff A, Eickhoff A. Rare statin hepatotoxicity: convincing evidence based on breakthrough case study. J. Hepatol. 2012; 57: 699-700.
36. Schulze J, Glass X. Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions. J. Hepatol. 2012; 57: 702-703. author reply 3-4.
37. Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: council for International Organizations of Medical Sciences scale for causality assessment. World. J. Hepatol. 2014; 6: 17-32.
38. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J. Hepatol. 2000; 33: 949-952.
39. Aithal GP, Watkins PB, Andrade RJ etal. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011; 89: 806-815.
40. Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World. J. Gastroenterol. 2013; 19: 2864-2882.
41. Teschke R. Hepatotoxicity associated with statins. Ann. Hepatol. 2012; 11: 418-420.
42. Davern TJ, Chalasani N, Fontana RJ etal. Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011; 141: 1665-1672.
43. Dalton HR, Fellows HJ, Stableforth W etal. The role of hepatitis E virus testing in drug-induced liver injury. Aliment. Pharmacol. Ther. 2007; 26: 1429-1435.
44. Teschke R, Eickhoff A, Schulze J. Drug and herb induced liver injury in clinical and translational hepatology: causality assessment methods, quo vadis? J. Clin. Translat. Hepatol. 2013; 1: 59-74. Available from URL: http://www.jcthnet.com/images/fulltext/v1i1/9_TeschkeR-JCTH-D-13-002.pdf.